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Abstract
Background—Little is known about differences in Barrett’s esophagus (BE) characteristics by 
sex, and race/ethnicity, or these differences in response to radiofrequency ablation (RFA).
Objective—We compared disease-specific characteristics, treatment efficacy, and safety 
outcomes by sex and race/ethnicity in patients treated with RFA for BE.
Design and Setting—The U.S. RFA Patient Registry is a multicenter collaboration reporting 
processes and outcomes of care for patients treated with RFA for BE.
Patients and Interventions—Patients with BE treated with RFA.
Main outcome measurements—We assessed safety (stricture, bleeding, perforation, 
hospitalization), efficacy (complete eradication of intestinal-metaplasia (CEIM)), complete 
eradication of dysplasia, and number of treatments to CEIM by sex and race/ethnicity.
Results—Among 5521 patients (4052 males; 5126 Caucasian, 137 Hispanic, 82 African-
American, 40 Asian, 136 not identified), females were younger (60.0 vs. 62.1 yrs.), had shorter BE 
(3.2 vs. 4.4 cm), and less dysplasia (37% vs. 57%) than males. Females were almost twice as 
likely to stricture (OR 1.7; 95% CI, 1.2–2.3). Although Caucasians were predominantly male, 
about half of African-Americans and Asians with BE were females. African-Americans and 
Asians had less dysplasia than Caucasians. Asians and African-Americans had more strictures 
than Caucasians. There were no sex or race differences in efficacy.
Limitations—Observational study with non-mandated paradigms, no central lab for re-
interpretation of pathology
Conclusions—In the U.S. RFA Registry, females had shorter BE and less aggressive histology. 
The usual male sex predilection for BE was absent in African-Americans and Asians. Post-
treatment stricture was more common among females, and Asians. RFA efficacy did not differ by 
sex or race.
Keywords
Barrett’s esophagus; radiofrequency ablation; sex; race
Introduction
Barrett’s esophagus (BE) is a precancerous condition associated with a 10 to 30-fold 
increased risk of esophageal adenocarcinoma, a cancer with an approximately 6-fold 
increase in incidence over the past four decades (1–6). Radiofrequency ablation (RFA) is an 
effective and safe therapy for eradication of nondysplastic and dysplastic BE (7, 8). Past 
studies demonstrate a strong association of BE with male sex and Caucasian race (9–12). 
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However, little is known about sex and racial differences in the characteristics of BE among 
patients undergoing endoscopic therapy for BE. Similarly, the impact of sex and race on the 
response to RFA treatment is unknown.
Sex and race discrepancies in the incidence of esophageal adenocarcinoma are well 
established, with a male to female ratio of 3 to 8:1, and a Caucasian to African-American 
ratio of 5:1 (12–16). Sex and race differences have also been reported for Barrett’s 
esophagus, which is 2 to 4 times as prevalent among males as females and five times as 
prevalent among Caucasians as African-Americans and Asians (10, 17–19). However, most 
of these studies are restricted by small numbers of minority patients and females, and are 
therefore limited in their ability to assess for sex and race differences in disease patterns. 
Previous studies of ablation therapy for BE also have had similar shortcomings with respect 
to numbers of females and minorities (7, 8, 20–22)
The aim of this study was to assess sex and race/ethnicity differences in the characteristics 
of BE in patients undergoing radiofrequency ablation for BE. Additionally, we investigated 
the impact of sex and race/ethnicity on RFA treatment efficacy and safety outcomes using a 
nationwide, multicenter registry of patients with BE.
Material and Methods
U.S. RFA Patient Registry
The U.S. RFA Patient Registry is a multicenter collaboration reporting processes and 
outcomes of care for patients treated with RFA for BE at 148 institutions in the United 
States (113 community-based, 35 academic-affiliated). The registry does not mandate 
protocols for care, but provides a suggested protocol for treatment and follow-up of patients 
with Barrett’s esophagus. The registry was developed as a research tool to monitor clinical 
outcomes in patients undergoing treatment of BE with RFA using the HALO Ablation 
Systems (GI Solutions, Sunnyvale, Calif, a subsidiary of Covidien), and is funded by 
Covidien, Inc. All physicians participating in this registry either elected to use Western 
institutional review board (IRB) approval, or obtained IRB approval through their respective 
institutions.
Patient Eligibility
Patients were enrolled from July 2007 to July 2011. Patients were eligible for inclusion in 
the registry if: (1) they had endoscopic evidence of columnar metaplasia in the tubular 
esophagus with accompanying biopsies demonstrating intestinal metaplasia, and (2) they 
received RFA for BE. Subjects were classified using standardized histological grading, 
including non-dysplastic BE (NDBE), indefinite for dysplasia (IND), low-grade dysplasia 
(LGD), high-grade dysplasia (HGD), intramucosal carcinoma (IMC), and invasive 
adenocarcinoma (EAC)(23). Those patients who had previously received one or more RFA 
treatments before enrollment had collection of retrospective data, with subsequent 
prospective collection of data for ensuing visits. Patients who had not yet undergone 
treatment were prospectively enrolled in the study.
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Data Collection and Database Collation
Information collected in the registry includes demographic data, histology before treatment, 
endoscopic findings, number of treatment sessions, ablation outcomes, and adverse events. 
Race/ethnicity were classified using race/ethnic categorizations as suggested by the National 
Institutes of Health (ethnicity of Hispanic/non-Hispanic and race of Caucasian, African-
American, American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific 
Islander). In this analysis, American Indian, Alaska Native, Hawaiian/Pacific Islander, and 
Asian were collapsed into a single categorization, due to small count data in those cells. 
Subjects who self-classified into more than one group were included in the non-Caucasian 
group to which they identified. All data were recorded on standardized case report forms 
(CRFs), and were entered online through an internet-based secured data entry and 
processing system. All CRFs are coded with a site code and patient code; no information 
identifying patients was contained on Registry documents. Data were collated into a central 
electronic database, with real-time monitoring for logic checks and consistency. Data were 
analyzed by investigators in the clinical epidemiology program at the UNC Center for 
Gastrointestinal Biology and Disease (T32 DK07634), who had complete access to the data.
Treatment Protocol
Data from previous clinical trials were given to all physicians as a guideline for treatment 
and follow-up protocols. However, because this is a registry study, institutions and 
individual physicians could deviate from the treatment protocols suggested, depending on 
individual patient requirements and physician preferences. The suggested treatment protocol 
provided to physician investigators has been previously described (23).
At enrollment, each patient was interviewed and a Baseline Encounter Form, which 
collected medical history information and demographics, was completed. The standardized 
protocol suggested medical therapy with twice-daily PPIs to minimize any baseline 
inflammatory changes of the esophageal mucosa and decrease acid reflux before and 
throughout RFA treatment, unless the patient had a documented history of antireflux 
surgery.
At the initial visit, patients were treated with one of two ablation devices: the HALO360 
Circumferential Ablation System or the HALO90 Focal Ablation System. The decision as to 
initial treatment modality was based on the burden of disease (Barrett’s segments of >3 cm 
are generally best treated with the circumferential catheter), as well as operator preference. 
Recommended treatment protocols were based on previously published data (24).
Follow-Up Protocol
Recommendations for the first follow-up visit, which was 2–3 months after treatment 
initiation, included additional circumferential or focal RFA treatment for any visible residual 
BE, depending on the extent of the disease. If no visible BE was observed, four-quadrant 
biopsies every cm were recommended throughout the length of the pre-treatment BE. If 
these biopsies were clear of BE on pathologic review, the patients entered the surveillance 
phase of follow-up. Initial surveillance was recommended at 3 months for those patients 
with HGD or 6 months for those patients with NDBE, IND, or LGD. If follow-up biopsies 
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revealed IM or dysplasia, recurrent treatment with RFA was recommended at the next 
endoscopy session.
Adverse events were reported using standardized forms and terminology. Each site also 
complied with reporting guidelines for their institution regarding reporting adverse events to 
their IRB and FDA under the MDR reporting regulation in 21 C.F.R. Part 803.
Outcomes
Safety outcomes included esophageal perforation, stricture formation, gastrointestinal (GI) 
bleeding, and hospitalization. A stricture was defined as any narrowing of the esophageal 
lumen requiring dilation. GI bleeding was considered clinically significant if hospitalization 
and/or blood transfusion was required. All patients treated with RFA were included in the 
safety analysis. Adverse event rates were reported per patient by sex and race group.
The rates of complete eradication of intestinal metaplasia (CEIM), rates of complete 
eradication of dysplasia (CED), and the number of RFA sessions were determined to assess 
the efficacy of treatment. CEIM was defined as an esophageal biopsy session in which no 
biopsy demonstrated IM, occurring at least 12 months after initial treatment. CED was 
defined as the absence of dysplasia (including indefinite dysplasia, LGD, HGD or worse) 
from biopsy specimens. All review was performed by local pathologists; results were 
reported on a standardized pathology form that specifically queried for the presence of 
intestinal metaplasia and dysplasia.
Efficacy analysis was restricted to patients who have been in the registry for at least 12 
months beyond treatment initiation and who had a biopsy performed 12 months or more 
after initial treatment.
Statistical Analysis
Statistical analysis was performed using Stata software (version 12.0; StataCorp LP, College 
Station, TX). Means and standard deviations were reported for continuous variables, and 
percentages were reported for continuous variables. Efficacy and safety outcomes were 
reported for patients in different sex and racial groups. Comparative analyses were 
performed with the Student t test or the Wilcoxon rank sum test for continuous variables, 
and Pearson χ2 test or the Fisher exact test for categorical variables. P values less than 0.05 
were considered statistically significant. We performed multivariable logistic regression to 
compare stricture rates and efficacy outcomes between males and females, using predictor 
variables suggested by the bivariate analysis (p<0.2). These models were reduced using the 
likelihood ratio test to assess for independent associations between sex/race and stricture or 
CEIM. Due to the small numbers in some ethnic groups, logistical regression could not be 
performed by race.
Results
A total of 5521 patients with BE were enrolled in the U.S. RFA Patient Registry between 
July 2007 and July 2011 from 148 institutions. Of these patients, 4052 (73.4%) were males 
and 5126 (92.8%) were Caucasian. Pre-treatment histology included: 2674 (48.3%) NDBE, 
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406 (7.4%) IND, 1113 (20.2%) LGD, 1054 (19.1%) HGD, 209 (3.8%) IMC, and 65 (1.2%) 
EAC (Table 1). The mean length of BE segment was 4.1 ± 3.3 cm with an average of 2.8 ± 
1.8 RFA treatment sessions were performed. 1541 (27.9%) patients were treated at an 
academic center. 320 (20.8%) of patients treated at an academic center had NDBE at 
baseline compared to 2354 (59.1%) of patients treated at a community practice.
BE characteristics and outcomes by sex
Of the 5521 patients who underwent RFA, 1469 (26.6%) were females. Females were 
somewhat younger in age (60.0 years vs. 62.1 years, p<0.001) and had shorter length of BE 
than males (3.2 cm vs. 4.4 cm, p<0.001) (Table 2). A higher proportion of females with BE 
were non-Caucasian than males (9.5% vs. 6.3%, p<0.001). Additionally, females were 
markedly less likely to have dysplastic BE than males (36.8% vs. 56.9%, p<0.001). In the 
safety analysis, we found that females were less likely to be hospitalized than males (0.3% 
vs. 1.0%; p = 0.013). Among the 5 female patients who were hospitalized, 1 was admitted 
with abdominal pain, 2 with chest pain, 1 with mucosal tear, and 1 with heart block. Among 
the 42 male patients who were hospitalized, 20 (48%) were admitted with upper GI 
bleeding, 5 (12%) with abdominal pain, 3 (7%) with chest pain, and 14 (33%) for other 
unknown reasons. There were no statistically significant differences in GI bleeding or 
perforation rates between females and males in our bivariate analysis. However, females 
were almost twice as likely as males to develop stricture (OR 1.7; 95% CI, 1.2 – 2.3) in 
multivariate logistic regression analysis, after adjusting for baseline level of dysplasia (IND 
or worse), race, length of BE segment, EMR treatment before RFA, pre-treatment 
fundoplication, treatment at academic center, age, PPI compliance, and the number of total 
RFA treatment sessions (Table 3).
Of the 5521 patients, 4118 (1067 females and 3051 males) had a biopsy session performed 
12 months or more after initial treatment and thus were included in our gender efficacy 
analysis. The comparisons of BE characteristics between females and males in the efficacy 
cohort were similar to that in safety cohort. Slightly fewer RFA sessions were required for 
females to achieve CEIM (2.8 vs. 3.2, p< 0.001) (Table 2), although this association 
dissolved in multivariable regression analysis. In bivariate analysis, females had a higher 
CEIM rate compared to males (89% vs. 84%, P<0.001), however, after controlling for age, 
length of BE segment, and the number of total RFA treatment sessions, and treatment 
settings, there were no sex differences in CED or CEIM rates in multivariable logistic 
regression analysis (Table 3).
BE characteristics and outcomes by race/ethnic group
Among the 5521 patients who underwent RFA for treatment of BE, 5126 were Caucasians, 
82 were African American, 40 were Asian/Pacific Islander and 137 were of Hispanic 
ethnicity. 136 patients were of unknown race/ethnicity and thus were excluded from the 
safety analysis. There were marked baseline differences between the groups in sex 
distribution, age, BE length, and severity of pretreatment histology (Table 4). Although 
Caucasians demonstrated the expected strong predilection toward male sex (74%), there was 
a near even distribution between the sexes in African Americans (male sex, 50%) and 
Asians (male sex, 53%) (p < 0.001). Caucasians had longer pre-treatment BE length 
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compared to all the other racial groups (4.1 cm Caucasians, 3.8 cm Hispanics, 3.1 cm 
African Americans, 2.2 cm Asians; p < 0.001) and were markedly more likely to have 
baseline dysplasia compared to other races (52% Caucasians, 36% Hispanics, 33% African 
Americans, 35% Asians; p < 0.001). Hispanics and African Americans were diagnosed and 
treated for BE at a younger mean age (Hispanics 58.2 years, African Americans 58.6 years, 
Caucasians 61.7 years, Asians 63.6 years; p < 0.001). There were no significant difference in 
the rates of GI bleeding, perforation, or hospitalization among different racial groups, but 
Asians had a significantly higher stricture rate compared to Caucasians (10.0% vs. 4.1%; p = 
0.02) (Table 4). Among females, stricture rate is 4.8% (26 out of 541) among patients with 
dysplastic BE, and 4.8% (45 out of 928) among patients with non-dysplastic BE. Among 
males, stricture rate is 5.6% (130 out of 2306) among patients with dysplastic BE, and 1.8% 
(32 out of 1746) among patients with non-dysplastic BE. Among the 43 Caucasians who 
were hospitalized, 17 (40%) were admitted with upper GI bleeding, 5 (12%) were with chest 
pain. Among the 2 Hispanics who were hospitalized, one was admitted with abdominal pain, 
and the other was admitted with upper GI bleeding.
Of the 5521 patients, 4004 patients (3825 Caucasians, 93 Hispanics, 54 African Americans, 
and 32 Asians) had a biopsy session performed 12 months or more after initial treatment and 
were included in the racial efficacy analysis. An additional 114 patients had a biopsy session 
performed 12 months or more after initial treatment but were with unreported race/ethnicity, 
and therefore they were excluded. The comparisons of BE characteristics among different 
racial groups in the efficacy cohort were similar to that in safety cohort. There were no 
significant differences in the rate of CEIM or number of RFA sessions to achieve CEIM in 
bivariate or multivariable analysis (Table 4).
Discussion
In the largest reported cohort of patients treated with RFA for BE, there were marked 
differences in BE disease patterns noted between different sex and race/ethnicity groups. In 
this registry, females and non-Caucasians had shorter length of BE and less aggressive 
baseline histology compared to males and Caucasians, respectively. Additionally, there was 
a complete lack of male sex predilection for BE in African Americans and Asians. In 
multivariate logistic regression analysis, strictures were almost twice as frequent among 
females as males. CEIM and CED efficacy outcomes were comparable across sex and race.
Previous studies have reported the male-to-female sex ratio of Barrett’s esophagus to be 
approximately 2 to 4:1; however, this ratio is very likely to be driven by the sex ratio of the 
dominant Caucasian group in these studies (10, 17–19). In the present study, male-to-female 
ratio was assessed by race. The male-to-female sex ratio among Caucasians was 
approximately 3:1, which is consistent with previous findings (10, 17, 18). Khoury et al. 
examined BE dysplasia prevalence among various ethnic groups (25). Although they found 
that most patients were male in all racial groups, there was a higher percent of females in the 
African American and other category (females: 31% non-Hispanic whites, 44% African 
Americans, 50% other). Similarly, our study found that sex ratios were more evenly 
distributed among African Americans and Asians (male-to-female ratio, 1:1). The reason for 
the different sex ratios in the races is not known. Perhaps the differential effects of obesity, 
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differences in diet, cultural differences in healthcare utilization by sex, or referral bias by 
physicians may play a role in detection and severity of BE. Similarly, the reason for the 
increased stricture rate among females, African-Americans and Asians is unclear. Whether 
this represents differences in the healing process by sex/race, differences in the depth of 
injury or other factors is unclear.
The impact of gender on CEIM remains unclear. In this registry, there were no sex 
differences in CED or CEIM rates in multivariable analysis. Haidry et al. and Gupta et al. 
have also shown no gender effect on CEIM rates. In contrast, however, a study by Qumseya 
et al. found that females take a longer time to achieve CEIM and have a 55% decreased rate 
in CEIM compared to males (22, 26, 27). This study was limited in that it was a single-
center, retrospective study with small numbers of females.
Few studies have examined differences in race/ethnicity among patients with BE. Fan and 
Snyder investigated race, age and sex differences between patients with and without 
gastroesophageal reflux disease (GERD) symptoms (28). Among 5019 patients who 
underwent endoscopy, 77 patients had confirmed histologic BE. There was no statistically 
significant association between prevalence of BE and racial/ethnic group (categorized as 
Caucasian, Hispanic, African American, and “other”), after adjusting for GERD symptoms. 
Using the Clinical Outcomes Research Initiative database, Wang et al. evaluated ethnic 
trends in patients with complicated reflux disease and suspected BE (29). The authors found 
increased esophageal strictures in white-non-Hispanic patients. However, this study was 
limited in that patients were included with “suspected” BE based on endoscopy findings, not 
histologically proven BE. Additionally, racial groups were based on provider assignment 
instead of patient designation, which increases susceptibility to bias. Khoury et al. found that 
among 115 patients with histologically confirmed BE, although non-statistically significant, 
non-Hispanic whites had increased dysplasia (7% non-Hispanic whites vs. 0% African 
Americans and Others; p = 0.763) (25). These studies are limited by small overall patient 
sizes and therefore few people in each ethnic group.
Importantly, our study focuses specifically on subjects enrolled in the United States. RFA 
registry undergoing RFA for BE, not a general and universal BE population. Our 
observations should not be generalized to all patients with BE, or even all patients who have 
undergone ablative therapy. Although our results are internally consistent, and represent 
differences between races and sexes in patients being referred for RFA at this large group of 
centers, the differences we see may be due to a number of factors. The differences in disease 
characteristics and outcomes may represent true biological differences between the groups. 
Alternatively, they may represent differences introduced by referral bias. For instance, if the 
finding of BE in a Hispanic patient or an African-American patient elicits more concern in a 
practitioner due to its relatively rare nature, that might in turn induce a referral for ablation. 
This bias might cause the proportion of subjects in these minority groups who have non-
dysplastic BE in our study to be higher. Because we have no data on subjects with BE who 
were seen at these centers but not referred for RFA, we cannot address the relative effects of 
biology versus referral bias on these data. Because our data represent a broad cross-section 
of RFA performed in private practices and academic centers, their real value is in their 
utility to inform similar patients as to their likely outcomes. In terms of generalizability to 
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the BE population, it is notable that many of the previously reported findings for Caucasian 
populations with respect to male predominance of dysplasia, as well as BE length 
differences are replicated in our study (30, 31). Even if any un-measurable bias is operative 
with respect to the subjects enrolled in the study, the safety and efficacy treatment data 
should accurately reflect the outcomes in this patient cohort by sex and race.
There are several strengths to our study. Our study assesses the sex and race differences in 
safety and efficacy outcomes of patients treated with RFA for BE, and our cohort was large 
enough to provide adequate numbers of patients for analysis in multiple race/ethnicity 
categories. Our study offers prognostic information to patients who are not in the white male 
category, the demographic forming the majority of previous studies. In addition, as our 
study is a nationwide multicenter registry study that includes both academic-affiliated and 
community-based institutions from 148 institutions, our results are more representative of 
real-life practices than tertiary care center reports. This improves the external validity of our 
results and increases the generalizability. Furthermore, study definitions were a priori, and 
data were collected in a standardized fashion.
Our study has several limitations that must be considered. Because we used the nationwide 
RFA registry for our analysis, our study was strictly observational and we could not mandate 
care paradigms. Patients with NDBE who were treated with RFA were included in this 
registry, although some experts do not recommend treating these patients with RFA (32). 
Additionally, as there were a broad range of providers in this registry, it is conceivable that 
perhaps there were mistakes in disease definitions, such as patients with irregular Z lines 
were mis-diagnosed with Barrett’s esophagus. However, we do not believe that these 
potential errors would preferentially occur in one racial group or gender. Given the size and 
nature of our study, and in line with other registry studies, there was no central lab for re-
interpretation of pathological specimens, thus, as in all studies such as this, interobserver 
variation in the interpretation of biopsy specimens likely introduces error into our study (26, 
33, 34). As this was a registry study with study outcomes defined a priori, we were often 
unable to collect specific details for each individual subject such as the reason for 
hospitalization or whether patients were symptomatic from strictures, etc.
Our research has several important implications for clnical practice. First, perhaps the utility 
of gender as a risk factor for the presence of BE may be lower in minority populations than 
in Caucasians given the lack of gender difference for BE in African Americans and Asians,. 
Second, given that females and Asians had increased stricture rates, we should be cautious 
about over-treatment in this patient population, and re-consideration of dosimetry in these 
patients may be necessary. This is especially true given the reduced length of BE and 
generally lower degree of dysplasia we found in women compared with men. Third, should 
females and Asians present with dysphagia symptoms after RFA, this population is more 
likely to reveal a stricture that may be amenable to endoscopic intervention, compared to 
Caucasian populations.
In conclusion, in this large U.S. registry of RFA treatment for BE, marked differences in 
disease patterns were noted between different races or sex. Most notable, a lack of the usual 
male sex predilection for BE in African-Americans and Asians was noted. Strictures were 
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more frequent after RFA among females and Asians. Importantly, efficacy outcomes did not 
differ by gender or race.
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Acronyms
BE barrett’s esophagus
RFA radiofrequency ablation
NDBE non-dysplastic barrett’s esophagus
IND indefinite for dysplasia
LGD low-grade dysplasia
HGD high-grade dysplasia
IMC intramucosal carcinoma
EAC invasive adenocarcinoma
CEIM complete eradication of intestinal metaplasia
CED complete eradication of dysplasia
GERD gastroesophageal reflux disease
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Table 1
Baseline Characteristics of all patients enrolled in the U.S. RFA Registry
All Patients Treated with RFA for BE (n= 5521)
Age (mean ± SD, years) 61.6 ± 11.4
Race/Ethnicity, n (%)
 Caucasian 5126 (92.8)
 African-American 82 (1.5)
 Hispanic 137 (2.5)
 Asian/Pacific Islander 40 (0.7)
 Unreported 136 (2.5)
Male gender, n (%) 4052 (73.4)
Length of BE segment (mean ± SD, cm) 4.1 ± 3.3
Pre-treatment fundoplication, n (%) 295 (5.3)
Pre-treatment histology, n (%)
 Nondysplastic 2674 (48.3)
 Indefinite dysplasia 406 (7.4)
 Low-grade dysplasia 1113 (20.2)
 High-grade dysplasia 1054 (19.1)
 Intramucosal carcinoma 209 (3.8)
 Invasive adenocarcinoma 65 (1.2)
Taking twice daily PPI, n (%) 4359 (79.0)
Total RFA treatments, (mean± SD) 2.8 ± 1.8
 Circumferential treatments 0.7 ± 1.0
 Focal treatments 2.1 ± 1.5
Total biopsies performed, (mean± SD) 2.8 ± 2.1
EMR treatment before RFA, n (%) 495 (9.0)
Treatment at an academic medical center, n (%) 1541 (27.9)
Total number of physicians, n 247
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Table 2
Baseline characteristics and safety and efficacy outcomes by sex
Females Males P-value
Safety cohort
Baseline Characteristics
N 1469 4052
Age (mean ± SD, years) 60.0 ± 11.4 62.1 ± 11.4 <0.001
Race/Ethnicity, n (%)
 Caucasian 1330 (90.5) 3796 (93.7) <0.001
 Black 41 (2.8) 41 (1.0)
 Hispanic 44 (3.0) 93 (2.3)
 Asian/Pacific Islander 19 (1.3) 21 (0.5)
 Unreported 35 (2.4) 101 (2.5)
Length of BE (mean ± SD, cm) 3.2 ± 2.8 4.4 ± 3.4 <0.001
Dysplastic at baseline (IND or worse), n (%) 541 (36.8) 2306 (56.9) <0.001
Outcomes, n (%)
Stricture 71 (4.8) 162 (4.0) 0.17
GI bleed 3 (0.2) 25 (0.6) 0.06
Perforation 0 2 (0.05) 0.39
Hospitalization 5 (0.3) 42 (1.0) 0.013
Efficacy cohort
Baseline Characteristics
N 1067 3051
Age (mean ± SD, years) 60.5 ± 11.4 62.3 ± 11.0 <0.001
Race/Ethnicity, n (%)
 Caucasian 962 (90.2) 2863 (93.8) <0.001
 Black 28 (2.6) 26 (0.9)
 Hispanic 32 (3.0) 61 (2.0)
 Asian/Pacific Islander 16 (1.5) 16 (0.5)
 Unreported 29 (2.7) 85 (2.8)
Length of BE (mean ± SD, cm) 3.2 ± 2.8 4.5 ± 3.4 <0.001
Dysplastic at baseline (IND or worse), n (%) 413 (39) 1811 (59) <0.001
Outcomes
CE-D, n/N (%) 386/413 (93) 1695/1811 (94) 0.99
CE-IM, % 954 (89) 2569 (84) <0.001
Total RFA treatment sessions, (mean ± SD) 2.8 ± 1.9 3.2 ± 1.9 <0.001
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Table 3
Multivariate analysis for sex differences in safety and efficacy outcome
Odds ratio (95%CI) Base model Reduced model
Safety outcome (stricture rate)
Female 1.67 (1.24 – 2.26) 1.36 (1.21 – 2.20)
Non-Caucasian 1.55 (0.99 – 2.42) 1.58 (1.02 – 2.47)
BE length, per cm 1.10 (1.06 – 1.15) 1.10 (1.07 – 1.15)
Pre-treatment dysplasia 1.39 (1.00 – 1.92) 1.54 (1.14 – 2.09)
Number of total RFA sessions 1.13 (1.06 – 1.19) 1.12 (1.06 – 1.19)
EMR treatment before RFA 1.51 (1.02 – 2.25) 1.64 (1.112.43)
Pre-treatment fundoplication 0.74 (0.39 – 1.42) --
Treatment at academic center 1.20 (0.89 – 1.62) --
Age, per year 1.01 (0.99 – 1.02) --
PPI compliant 0.58 (0.30—1.13) --
Efficacy outcome (CEIM rate)
Female 1.21 (0.96 – 1.52) 1.24 (0.99 – 1.55)
Age, per year 0.98 (0.97 – 0.99) 0.98 (0.97 – 0.99)
BE length, per cm 0.85 (0.83 – 0.88) 0.85 (0.83 – 0.87)
Treatment at academic center 1.29 (1.04 – 1.59) 1.26 (1.03 – 1.54)
Number of total RFA sessions 0.92 (0.88 – 0.96) 0.92 (0.88 – 0.96)
Pre-treatment dysplasia 0.85 (0.69 – 1.05) --
Non-Caucasian 0.91 (0.64 – 1.29) --
Pre-treatment fundoplication 0.96 (0.66 – 1.41) --
EMR treatment before RFA 0.87 (0.65 – 1.18) --
PPI compliant 1.56 (0.97–2.48) --
Base model: adjusting for all the variables listed in the table.
Reduced model: only adjusting for variables with an odds ratio provided.
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